Rare disease startup NFlection scores $20M in Series A haul; Gilead partner Galapagos signs pact with Oxford biotech
→ A Wayne, PA-based startup called NFlection has raised $20 million in their Series A launch round. F-Prime and venBio Partners provided the cash for the rare disease biotech, funding their first clinical trial for NFX-179 Gel in adult patients with cutaneous neurofibromatosis type-1, or NF-1. “This study allows us to determine the drug’s ability to suppress key biomarkers involved in the progression of neurofibromas and will aid in the selection of doses for a larger Phase 2b study,” said CEO Christopher Powala.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
